Boots To Unload OTC Business, Citing Market Consolidation
This article was originally published in The Rose Sheet
Executive Summary
Merger and acquisition activity in the OTC drug industry has prompted Boots the Chemists to put its healthcare unit up for sale
You may also be interested in...
Reckitt Spends $3.3 Bil. On Boots, Gains Clearasil Anti-Acne Brand
Reckitt Benckiser's $3.3 bil. (£1.9 bil.) cash purchase of Boots Healthcare International establishes the company as a significant player in the OTC consumer products market
Reckitt Spends $3.3 Bil. On Boots, Gains Clearasil Anti-Acne Brand
Reckitt Benckiser's $3.3 bil. (£1.9 bil.) cash purchase of Boots Healthcare International establishes the company as a significant player in the OTC consumer products market
Boots first half
Boots Healthcare International sales rose 7.6% in the first half, British company reports Sept. 29. In addition, "The proposed disposal of BHI is on track," firm notes. Boots announced it would divest its OTC consumer business in April (1"The Rose Sheet" April 11, 2005, p. 9). Boots the Chemists net sales were up 1.1%, but declined 1.3% on a like-for-like basis...